Baiji Shenzhou will hold a conference call at 7:00 p.m. EST on September 8, 2019 and conduct a live webcast response short report

On September 8, 2019, Baiji Shenzhou company announced that it would hold a teleconference on a short selling analysis report on the company's operation and broadcast it live online on September 8, 2019 (Sunday) at 7:00 p.m., Hong Kong time, Monday, September 9, 2019, before the opening of the Hong Kong Stock Exchange Teleconferencing and webcast information investors and analysts can listen to the teleconference by calling the following number: toll free in the United States: (844) 461-9930 Hong Kong: 5819-4851 mainland China: 400-682-8609 conference room ID: 7797578 At that time, the investor relations section of Baiji's official website (http://ir.beigene.com/ or http://hkexir.beigene.com) will broadcast the above speech live online Live playback records are available for viewing two hours after the end of the meeting and are archived for viewing within 90 days About Baiji Shenzhou, a global, commercial stage, R & D-based biotechnology company, focusing on the research and development of molecular targeting and immunotherapy for tumor At present, Baiji Shenzhou has more than 2700 employees in mainland China, the United States, Australia and Switzerland, and its research product line includes new oral small molecule and monoclonal antibody anti-cancer drugs At present, Baiji Shenzhou is also building a drug combination program for anti-cancer treatment, aiming to bring lasting and far-reaching impact on the life of cancer patients Under the authorization of Xinji company, Baiji Shenzhou sells Abraxane ® paclitaxel for injection (nano albumin particle binding type), refume ® (lenalidomide) and vedasha ® (azacytidine for injection) in China [1] [1] Abraxane ®, rifeme ® and vidasha ® are registered trademarks of new base Pharmaceutical Co., Ltd.